Composition for treating diabetes and metabolic diseases and a preparation method thereof

Abstract

Disclosed is a chalcone composition for treating diabetes and metabolic syndromes. In particular, the chalcone compound bound with 2-halogen in ring A significantly decreases the blood glucose level in the in vitro anti-diabetic effect experiment. In the in vivo animal model, the leading chalcone compound can prevent the progression of diabetes and control the blood glucose level, and there is no significant difference in the gains in body weight. Throughout the seven-week administration, there are no hepatic or renal toxicity observed.

What is claimed is: 
     
       1. A composition for treating one of a diabetes and a metabolic syndrome, comprising a chalcone compound represented by formula I: 
       
         
           
           
               
               
           
         
         wherein X is one of a bromide and an iodine, each of R1, R2, R3 and R4 is selected from a group consisting of a first hydrogen, a first hydroxide and a halogen, and each of R5, R6, R7, R8 and R9 is selected from a group consisting of a second hydrogen, a second hydroxide, a C 1  to C 20  alkoxy group and a benzyloxy group. 
       
     
     
       2. The composition according to  claim 1 , wherein the halogen is selected from a group consisting of a fluoride, a chloride, a bromide and an iodine. 
     
     
       3. The composition according to  claim 1 , wherein one of the diabetes and the metabolic syndrome occurs in a subject. 
     
     
       4. The composition according to  claim 3 , wherein the subject is one of a human being and a rodent. 
     
     
       5. The composition according to  claim 3 , wherein the subject has a blood glucose value, and the composition is effective in at least one treatment of regulating the blood glucose value and stabilizing the blood glucose value. 
     
     
       6. The composition according to  claim 3 , wherein the subject is subjected to at least one of an impaired glucose tolerance and a body weight gain, and the composition is effective in inhibiting at least one of the impaired glucose tolerance, the body weight gain and the accumulation of lipid droplets in adipocytes. 
     
     
       7. The composition according to  claim 1  further being effective in at least one treatment of inhibiting the metabolic syndrome and delaying the metabolic syndrome. 
     
     
       8. A composition for inhibiting a body weight gain, comprising a chalcone compound represented by formula I: 
       
         
           
           
               
               
           
         
         wherein X is one of a bromide and an iodine, each of R1, R2, R3 and R4 is selected from a group consisting of a first hydrogen, a first hydroxide and a halogen, and each of R5, R6, R7, R8 and R9 is selected from a group consisting of a second hydrogen, a second hydroxide, a C 1  to C 20  alkoxy group and a benzyloxy group. 
       
     
     
       9. The composition according to  claim 8 , wherein the body weight gain occurs in a subject. 
     
     
       10. The composition according to  claim 9 , wherein the subject is a mouse being continuously fed with a high fat diet and subjected to an impaired glucose intolerance, and the high fat diet has at least 40 weight percentage of fat. 
     
     
       11. The composition according to  claim 9 , wherein the subject has adipocytes, and the composition is used to inhibit the accumulation of lipid droplets in the adipocytes.